GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 17
- Registration Number
- NCT01101594
- Locations
- 🇺🇸
University Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Orlando, Orlando, Florida, United States
🇺🇸MD Anderson Center, Houston, Texas, United States
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
- Conditions
- Non Hodgkin's LymphomaNHLAggressive NHLDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01101581
- Locations
- 🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸MDACC Orlando, Orlando, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- HIV InfectionsHIV
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 707
- Registration Number
- NCT01095796
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Anthony Mills, MD, Inc., Los Angeles, California, United States
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
- Conditions
- Chronic Lymphocytic LeukemiaLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 202
- Registration Number
- NCT01090414
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin's LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT01088048
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
- Conditions
- HCV Infection
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT01072695
Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2011-05-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT01066611
- Locations
- 🇦🇹
Vienna Challenge Chamber, Vienna, Austria
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
- Conditions
- Cystic FibrosisBurkholderia Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT01059565
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
- Conditions
- Cystic FibrosisCFLung InfectionPseudomonas Aeruginosa
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT01055847
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 64
- Registration Number
- NCT01054729
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Alamo Medical Research Center, San Antonio, Texas, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States